Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT00786812
- Locations
- 🇧🇷
Novartis Investigative Site, São Paulo, SP, Brazil
A Study of Nilotinib Versus Imatinib in GIST Patients
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 644
- Registration Number
- NCT00785785
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Distrito Capital, Venezuela
🇺🇸Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States
🇺🇸Ocala Oncology Center Dept. of Ocala Oncology Center, Ocala, Florida, United States
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT00784212
- Locations
- 🇩🇪
Novartis Investigator Site, Radeberg, Germany
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 116
- Registration Number
- NCT00782067
- Locations
- 🇺🇸
Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, United States
🇺🇸University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(3), Ann Arbor, Michigan, United States
🇺🇸Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia, Augusta, Georgia, United States
Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2200
- Registration Number
- NCT00781105
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)Drug: Placebo
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 165
- Registration Number
- NCT00776009
- Locations
- 🇺🇸
Claghorn-Lesem Research Clinic, Houston, Texas, United States
🇺🇸Behavioral Neurology, Lubbock, Texas, United States
🇺🇸Clinical Study Center, LLC, Little Rock, Arkansas, United States
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00774020
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
🇨🇳Novartis Investigative site, Shanghai, China
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Biological: AIN457Biological: Placebo
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT00770965
- Locations
- 🇺🇸
Novartis Investigative Site, Nashville, Tennessee, United States
Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT00770601
- Locations
- 🇺🇸
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 9, Bethesda, Maryland, United States
Treatment of Patients With RAD001 With Progressive Sarcoma
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT00767819
- Locations
- 🇮🇹
Novartis Investigative Site, Milano, MI, Italy